(Video) Hims director responds to controversy, explains investment logic

This episode of the video focuses on the long-term investment thesis for Hims & Hers. Guest David Wells, from the perspective of a former Netflix CFO, discusses Hims' potential in telehealth, AI, wearable devices, weight loss business, subscription models, and the platformization of consumer healthcare. He believes the market may be underestimating Hims' long-term vision: it's not just an opportunistic company selling ED, hair loss, or GLP-1 weight loss products, but rather an attempt to reshape healthcare access through technology, integration of medical services, and direct-to-consumer experience. The video also delves into the 10b5-1 insider trading plan, the reasons behind the high short interest ratio, and why short-term metrics and stock price volatility shouldn't overshadow the greater platform value the company could achieve in the next three to five years.$Hims & Hers Health(HIMS.US)$Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)